Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.48 |
| ▸ | CCND1 | P24385 | 4/20 | 0.48 |
| ▸ | CCND3 | P30281 | 4/20 | 0.48 |
| ▸ | CDK6 | Q00534 | 4/20 | 0.48 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.48 |
| ▸ | CDK9 | P50750 | 2/20 | 0.48 |
| ▸ | CDK7 | P50613 | 1/20 | 0.48 |
| ▸ | CCNH | P51946 | 1/20 | 0.48 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.48 |
| ▸ | IDH1 | O75874 | 2/20 | 0.35 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 11/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20956353 | 0.99 | CDK4 (0.50) | CDK4CCND1CCND3CDK6CCNT1 | |
| SCHEMBL19402043 | 0.79 | RPS6KA5 (0.35) | CDK4CCND1CCND3CDK6CCNT1 | |
| SCHEMBL20956322 | 0.79 | CCNT1 (0.52) | CDK4CCND1CCND3CDK6CCNT1 | |
| SCHEMBL20956374 | 0.79 | CCND3 (0.54) | CDK4CCND1CCND3CDK6CCNT1 | |
| SCHEMBL14846570 | 0.78 | IDH1 (0.56) | IDH1 | |
| SCHEMBL20677023 | 0.74 | CDK4 (0.35) | CDK4CCND1CCND3CDK6CCNT1 | |
| SCHEMBL20956355 | 0.73 | CDK4 (0.39) | CDK4CCND1CCND3CDK6CCNT1 | |
| SCHEMBL20875127 | 0.71 | CCNT1 (0.43) | CDK4CCND1CCND3CDK6CCNT1 | |
| SCHEMBL20956336 | 0.71 | CDK4 (0.58) | CDK4CCND1CCND3CDK6IDH1 | |
| SCHEMBL16098386 | 0.70 | TNKS (0.38) | IDH1RPS6KA5TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3434674-B1 | ((4-(2-OXOIMIDAZOLIDINE-1-YL)PYRIMIDIN-2-YL)AMINE DERIVATIVES AS MUTANT IDH INHIBITORS FOR TREATING CANCER | SHANGHAI HAIHE PHARMACEUTICAL CO LTD (CN) | 2021-02-24 | — | — | EP | disclosed |
| US-10682352-B2 | Compound having mutant IDH inhibitory activity, preparation method and use thereof | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) | 2020-06-16 | — | — | US | disclosed |
| US-20190111056-A1 | COMPOUND HAVING MUTANT IDH INHIBITORY ACTIVITY, PREPARATION METHOD AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-04-18 | — | — | US | disclosed |
| EP-3434674-A1 | COMPOUND HAVING MUTANT IDH INHIBITORY ACTIVITY, PREPARATION METHOD AND USE THEREOF | Shanghai Haihe Pharmaceutical Co., Ltd. (CN) | 2019-01-30 | — | — | EP | disclosed |
| WO-2017162133-A1 | COMPOUND HAVING MUTANT IDH INHIBITORY ACTIVITY, PREPARATION METHOD AND USE THEREOF | 上海海和药物研究开发有限公司 | 2017-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190111056-A1 | COMPOUND HAVING MUTANT IDH INHIBITORY ACTIVITY, PREPARATION METHOD AND USE THEREOF | IDH1, IDH3A, IDH2 | CDK4 2218/4885CCND1 3808/4885CCND3 4440/4885 |
| US-10682352-B2 | Compound having mutant IDH inhibitory activity, preparation method and use thereof | IDH1, IDH3A, IDH2 | CDK4 2218/4885CCND1 3808/4885CCND3 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.